This study focuses on Ulcerative Colitis, a disease that causes inflammation and sores in the lining of the large intestine. The purpose of the study is to compare different types of advanced medicines used to keep the disease in a state of remission, which means a period where symptoms are minimal or absent. The medications being studied include ustekinumab, infliximab, filgotinib, and vedolizumab.

The treatments involve different methods of delivery. Some medicines, such as infliximab, ustekinumab, and vedolizumab, are given through intravenous infusion, which is a process where medicine is delivered directly into a vein. Another medicine, filgotinib, is taken as an oral tablet. These medications belong to different classes, including anti-TNF agents, anti-IL12/23, JAK inhibitors, and anti-integrins, which are specific ways that drugs work to target the parts of the immune system causing inflammation.

During the study, participants will receive one of these treatments to see how well it helps maintain health and manage the disease over time. The process involves regular monitoring to check for the disappearance of symptoms like rectal bleeding and changes in bowel habits. The study will observe how these different medicines perform in helping patients achieve long-term stability without the need for steroids, which are a type of medicine often used to reduce swelling and inflammation.